XTL Biopharmaceuticals Company

XTL Biopharmaceuticals Ltd is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE).
Industry: Genomic and Epigenominc Instabillity
Headquarters: Israel

Visit Website
info@xtlbio.com
Register and Claim Ownership